Antibody & Biosim...
Follow
Find
100 views | +0 today
Your new post is loading...
Your new post is loading...
Scooped by Freya Smale
Scoop.it!

Take part in the Biosimilars Survey – Bloomberg Intelligence

Take part in the Biosimilars Survey – Bloomberg Intelligence | Antibody & Biosimilar | Scoop.it
Bloomberg Intelligence have launched the Biosimilars Survey. This is your opportunity to have your voice heard. Take part in the survey here > All responders will receive a white paper and analysis of the results. That's not…
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

Ultraspecific and extensively validated monoclonal antibodies now available ... - News-Medical.net

Ultraspecific and extensively validated monoclonal antibodies now available ... - News-Medical.net | Antibody & Biosimilar | Scoop.it
AMSBIO has announced the availability of ultraspecific and extensively validated monoclonal antibodies under the UltraMAB™ brand.
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

Finding the Ebola virus' vulnerable points - Ars Technica

Finding the Ebola virus' vulnerable points - Ars Technica | Antibody & Biosimilar | Scoop.it
We know what antibodies stop it in its tracks—we now know where they attach.
more...
No comment yet.
Rescooped by Freya Smale from Virology and Bioinformatics from Virology.ca
Scoop.it!

How ZMapp antibodies bind to Ebola virus

How ZMapp antibodies bind to Ebola virus | Antibody & Biosimilar | Scoop.it
The structure of the antibodies in ZMapp bound to the Ebola virus glycoprotein reveal how they inhibit infection and how ZMapp might be improved.

Via Kenzibit
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

Who are the top 4 Players in 3D Antibody Characterization?

Who are the top 4 Players in 3D Antibody Characterization? | Antibody & Biosimilar | Scoop.it
Freya Smale's insight:

Who are the top 4 Players in 3D Antibody Characterization?
 

Therapeutic antibody engineering has been around for years. So what is keeping the number of therapeutic antibody treatments so relatively low when compared to small molecules and other types of therapeutics?
 

Antibodies, and their therapeutic derivatives such as antibody-drug conjugates (ADCs), are complex, multi-faceted molecules that often require immense amounts of characterization to take place both prior to and during the engineering phases. Through excellent characterization, quicker research with reduced overhead and risk will be enabled. However, 3D antibody modeling wasn’t always at its current state, and it still has a long way to go. In fact, a consortium of scientists recently set out to test the state of modeling software.
 

This eBook will go through the top characterization players currently working with the industry, based on feedback from biopharma companies themselves, as well as participation in these aforementioned consortium, helping both the field and each other learn from the current gaps in the systems.

Download this eBook now

more...
Freya Smale's curator insight, November 25, 2014 12:25 PM

Therapeutic antibody engineering has been around for years. So what is keeping the number of therapeutic antibody treatments so relatively low when compared to small molecules and other types of therapeutics?
 

Antibodies, and their therapeutic derivatives such as antibody-drug conjugates (ADCs), are complex, multi-faceted molecules that often require immense amounts of characterization to take place both prior to and during the engineering phases. Through excellent characterization, quicker research with reduced overhead and risk will be enabled. However, 3D antibody modeling wasn’t always at its current state, and it still has a long way to go. In fact, a consortium of scientists recently set out to test the state of modeling software.
 

This eBook will go through the top characterization players currently working with the industry, based on feedback from biopharma companies themselves, as well as participation in these aforementioned consortium, helping both the field and each other learn from the current gaps in the systems.

Download this eBook now

Scooped by Freya Smale
Scoop.it!

Americas Antibody Congress: Launching May 27-28, 2015 - Total Biopharma : Total Biopharma

Americas Antibody Congress: Launching May 27-28, 2015 - Total Biopharma : Total Biopharma | Antibody & Biosimilar | Scoop.it
Freya Smale's insight:

Over the past 10 years we have been working with the antibody industry to create our Antibody Congress series. We have a proud track record in Europe, Asia and now with this knowledge we are launching into America in 2015.

 

Download the event prospectus to find out how you can get involved >
 

The US is projected to become the largest single market for therapeutic mAbs from $20.1B in 2011 to to $27.4B by 2016. Although there have been a number of mAbs entering the market, with high development costs, and time-consuming R&D and clinical trials making it difficult to gain faster entry into the US market. The therapeutic potential is still enormous. By addressing these issues head on, attendees at the Americas Antibody Congress will have the opportunity to gain insight from industry innovators and disruptors; do business with solution providers in the exhibition; crowd source in roundtable sessions enabling you to tailor your audience to suit your business needs; and also network with your peers with our 1-2-1 partnering system, but also having loads of fun at the Terrapinn garden party.
 

Event features:

2-day conference incorporating content on mAbs, ADCs and bi-specificsShared 30 exhibition booths with Cell Culture World Congress, Downstream Processing World and World Biosimilar Congress USA300 + of your peers from across the biopharma industry all under one roof50 + speakers from across the antibody industry20 + hours of networking

 

Speak alongside your industry peers such as:

Steve Sazinsky, Senior Scientist, Antibody Discovery,  Jounce Therapeutics, Inc.Puja Sapra, Senior Director,  PfizerJohn Lambert, EVP and CSO, ImmunogenSyd Johnson, Vice President of Antibody Engineering, MacrogenicsAndrew Hiatt, CSO, Mapp BiopharmaceuticalsSteven  Coats, Director of Cancer Research, MedImmuneBill Zamboni,  Director, GLP Analytical Facility, U.N.C. Eshelman School of Pharmacy
 

Want to get involved? Call Jose today on +1 646 619 1781.

more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

Sorrento awarded up to $2.6M from NIH for bispecific antibodies ...

Sorrento awarded up to $2.6M from NIH for bispecific antibodies ... | Antibody & Biosimilar | Scoop.it
Sorrento Therapeutics, a late-stage clinical oncology company developing new treatments for cancer and its associated pain, has received two NIH small business grants, which will fund the development of bispecific ...
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune | News - ADC Therapeutics

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune | News - ADC Therapeutics | Antibody & Biosimilar | Scoop.it
ADC Therapeutics to Move #ADC ADCT-401 for #prostatecancer into Human Clinical Trials with Partner MedImmune http://t.co/7ZsdUlMgRf
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

Monoclonal antibody pinpoints BRAF status in melanoma - Skin and Allergy News Digital Network

Monoclonal antibody pinpoints BRAF status in melanoma Skin and Allergy News Digital Network DENVER - A murine monoclonal antibody had very high sensitivity and specificity for melanomas with the V600E BRAF mutation, and exhibited perfect...
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

Anti-CD47 antibody may offer new route to successful cancer vaccination - Office of Communications & Public Affairs - Stanford University School of Medicine

Anti-CD47 antibody may offer new route to successful cancer vaccination - Office of Communications & Public Affairs - Stanford University School of Medicine | Antibody & Biosimilar | Scoop.it
Anti-CD47 antibody may offer new route to successful cancer vaccination - Stanford University School of Medicine http://t.co/KPxoiI0Hz2
more...
No comment yet.
Rescooped by Freya Smale from Antibody & Biosimilar
Scoop.it!

With only a week to go, now is the time to book for the World Biosimilar Congress- Brochure available here

With only a week to go, now is the time to book for the World Biosimilar Congress- Brochure available here | Antibody & Biosimilar | Scoop.it

Join us next week when Geneva will become the place to discuss what is affecting the industry right now, including developing mAb biosimilars

more...
No comment yet.
Rescooped by Freya Smale from Biopharm
Scoop.it!

Another Mab Drug Approval - Gazyva

Another Mab Drug Approval - Gazyva | Antibody & Biosimilar | Scoop.it
Gazyva (guh-ZY-vuh) rode through the FDA today with an early approval as Genentech's heir apparent to rituxan for the treatment of CLL in combination with chemotherapy.

Via H. Fai Poon
more...
H. Fai Poon's curator insight, November 5, 2013 8:44 PM

Another cancer drug!

Scooped by Freya Smale
Scoop.it!

Antibody gives relief from hayfever - Telemanagement

Antibody gives relief from hayfever - Telemanagement | Antibody & Biosimilar | Scoop.it
Antibody gives relief from hayfever
Telemanagement
Omalizumab is a monoclonal antibody which blocks the action of a molecule called immunoglobulin E (IgE), the major culprit behind allergic conditions like hayfever.
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

Where in biosimilars is the devil?

Where in biosimilars is the devil? | Antibody & Biosimilar | Scoop.it
At long last, it’s only a matter of time before the first biosimilar will be approved by the FDA. The race to be the first 3 biosimilars in the USA is on! How do I…
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

Antibody Therapy Clears Alzheimer's Plaques in Mice

Antibody Therapy Clears Alzheimer's Plaques in Mice | Antibody & Biosimilar | Scoop.it
Antibodies against amyloid beta (Aβ) protein deposits that are thought to play a role in Alzheimer's disease have shown some success in preventing the buildup of deposits in animals, but they have ...
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

German Scientists create lab-grown spinal cords - ZME Science

German Scientists create lab-grown spinal cords - ZME Science | Antibody & Biosimilar | Scoop.it
For the first time, researchers in Germany have been able to create spinal cords in a Petri dish. To be more precise, they didn't grow complete spinal cord
more...
No comment yet.
Rescooped by Freya Smale from Antibody & Biosimilar
Scoop.it!

Who are the top 4 Players in 3D Antibody Characterization?

Who are the top 4 Players in 3D Antibody Characterization? | Antibody & Biosimilar | Scoop.it
Freya Smale's insight:

Therapeutic antibody engineering has been around for years. So what is keeping the number of therapeutic antibody treatments so relatively low when compared to small molecules and other types of therapeutics?
 

Antibodies, and their therapeutic derivatives such as antibody-drug conjugates (ADCs), are complex, multi-faceted molecules that often require immense amounts of characterization to take place both prior to and during the engineering phases. Through excellent characterization, quicker research with reduced overhead and risk will be enabled. However, 3D antibody modeling wasn’t always at its current state, and it still has a long way to go. In fact, a consortium of scientists recently set out to test the state of modeling software.
 

This eBook will go through the top characterization players currently working with the industry, based on feedback from biopharma companies themselves, as well as participation in these aforementioned consortium, helping both the field and each other learn from the current gaps in the systems.

Download this eBook now

more...
Freya Smale's curator insight, November 25, 2014 12:22 PM

Who are the top 4 Players in 3D Antibody Characterization?
 

Therapeutic antibody engineering has been around for years. So what is keeping the number of therapeutic antibody treatments so relatively low when compared to small molecules and other types of therapeutics?
 

Antibodies, and their therapeutic derivatives such as antibody-drug conjugates (ADCs), are complex, multi-faceted molecules that often require immense amounts of characterization to take place both prior to and during the engineering phases. Through excellent characterization, quicker research with reduced overhead and risk will be enabled. However, 3D antibody modeling wasn’t always at its current state, and it still has a long way to go. In fact, a consortium of scientists recently set out to test the state of modeling software.
 

This eBook will go through the top characterization players currently working with the industry, based on feedback from biopharma companies themselves, as well as participation in these aforementioned consortium, helping both the field and each other learn from the current gaps in the systems.

Download this eBook now

Rescooped by Freya Smale from Project Virtual Tumor Cancer in silico and Alternative Cancer Therapies
Scoop.it!

New imaging technique identifies receptors for targeted cancer therapy

New imaging technique identifies receptors for targeted cancer therapy | Antibody & Biosimilar | Scoop.it
A fluorescence imaging technique has been developed that can more accurately identify receptors for targeted cancer therapies without a tissue biopsy.

Via Miguel Martín-Landrove
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

'Wimpy' Antibody May Protect Against Kidney Disease - Bioscience Technology

'Wimpy' Antibody May Protect Against Kidney Disease - Bioscience Technology | Antibody & Biosimilar | Scoop.it
An antibody abundant in mice and previously thought to offer poor assistance in fighting against infection may actually play a key role in keeping immune responses in check and preventing more serious self-inflicted forms of kidney disease,...
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

Takeda signs option deal for MacroGenics bi-specific antibody

Takeda signs option deal for MacroGenics bi-specific antibody | Antibody & Biosimilar | Scoop.it
From BioPortfolio: Rockville, Maryland-based MacroGenics now has five partnerships related to its Dual-Affinity Re-Targeting (DART) technology for generating single molecules with...
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

MorphoSys and Temple University Sign Therapeutic Antibody Discovery ... - MarketWatch

MorphoSys and Temple University Sign Therapeutic Antibody Discovery ...
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression

Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression | Antibody & Biosimilar | Scoop.it
From BioPortfolio: (News: Met degradation by SAIT301 a Met monoclonal antibody reduces the invasion and migration of nasopharyngeal ca...
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

Europe’s leading event for High Potency API development and manufacture | HPAPI

Europe’s leading event for High Potency API development and manufacture | HPAPI | Antibody & Biosimilar | Scoop.it
Europe’s leading event for High Potency API development and manufacture
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

With only a week to go, now is the time to book for the World Biosimilar Congress- Brochure available here

With only a week to go, now is the time to book for the World Biosimilar Congress- Brochure available here | Antibody & Biosimilar | Scoop.it
Join us next week when Geneva will become the place to discuss what is affecting the industry right now, including developing mAb biosimilars
more...
No comment yet.
Scooped by Freya Smale
Scoop.it!

Monoclonal antibody (mAbs) 2013 | ORGANIC CHEMI...

Monoclonal antibody (mAbs) 2013 | ORGANIC CHEMI... | Antibody & Biosimilar | Scoop.it
2013-------29 monoclonal antibody (mAbs) drugs are in Phase III clinical development. While around 350 therapeutic mAbs are currently in clinical development globally, only 28 had entered active Ph...
more...
No comment yet.